L3VLUP
ProSign in

ARGX · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ARGXGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ARGX
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterARGXGILD
Q3 20208 holders, $3.6bn25 holders, $14.2bn
Q4 20207 holders, $4.1bn27 holders, $13.4bn
Q1 20218 holders, $4.1bn24 holders, $14.5bn
Q2 20219 holders, $4.6bn18 holders, $14.9bn
Q3 20218 holders, $4.5bn20 holders, $16.4bn
Q4 20219 holders, $5.3bn20 holders, $16.8bn
Q1 20228 holders, $5.3bn28 holders, $13.2bn
Q2 202213 holders, $6.5bn26 holders, $13.6bn
Q3 202214 holders, $5.3bn24 holders, $13.3bn
Q4 202213 holders, $5.5bn32 holders, $21.1bn
Q1 202313 holders, $5.9bn27 holders, $21.8bn
Q2 202318 holders, $6.6bn24 holders, $20.7bn
Q3 202321 holders, $8.7bn24 holders, $20.0bn
Q4 202317 holders, $6.3bn22 holders, $21.5bn
Q1 202413 holders, $6.8bn30 holders, $20.3bn
Q2 202414 holders, $7.9bn28 holders, $18.5bn
Q3 202413 holders, $10.7bn29 holders, $24.2bn
Q4 202414 holders, $12.3bn28 holders, $25.9bn
Q1 202517 holders, $11.8bn33 holders, $32.0bn
Q2 202518 holders, $10.8bn27 holders, $30.9bn
Q3 202516 holders, $13.8bn23 holders, $29.4bn
Q4 202516 holders, $14.8bn25 holders, $34.3bn
Q1 202611 holders, $12.3bn25 holders, $38.5bn
Q2 202614 holders, $15.0bn26 holders, $34.2bn
ARGX

Argenx Se

Holders
16
Reported value
$13.8bn
Buyers
10
Sellers
7

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
23
Reported value
$29.4bn
Buyers
9
Sellers
14

Breadth -5 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2025

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ARGX (8)

Artisan Partners LP, D. E. Shaw & Co., Hudson Bay Capital Management LP, Millennium Management LLC, Moore Capital Management LP, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC

Only GILD (15)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Dodge & Cox, Holocene Advisors LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →